Division of Circassia Pharmaceuticals PLC
Latest From Prosonix Ltd.
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.
Launch of the first FDA-approved subcutaneous allergy vaccine may be four years away, but the European specialty company is starting to plan for commercialization and market growth.
- Medical Devices
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Circassia Pharmaceuticals PLC
- Senior Management
David Hipkiss, CEO
Andy Bush, COO & CFO
Geoff Down, CMO
Cecile Miles, CBO
- Contact Info
Phone: 1865 784250
Robert Robinson Ave., Magdalen Centre
Oxford, OX4 4GA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.